Yes, the evidence strongly supports a **legacy effect (metabolic memory)** in both type 1 and type 2 diabetes, where **early intensive glycemic control** confers **long-term reductions in microvascular complications** and, to a lesser extent, **macrovascular outcomes**, with benefits persisting for decades even after glycemic differences diminish.

1. Introduction

The "legacy effect" or metabolic memory describes the phenomenon where early intensive glycemic control in diabetes leads to sustained reductions in long-term complications, even after subsequent glycemic control converges between treatment groups. Seminal studies such as the Diabetes Control and Complications Trial (DCCT) and its follow-up Epidemiology of Diabetes Interventions and Complications (EDIC) study for type 1 diabetes, and the United Kingdom Prospective Diabetes Study (UKPDS) for type 2 diabetes, have provided robust evidence that early intensive therapy reduces microvascular complications and, over extended follow-up, also lowers macrovascular events and mortality (Folz & Laiteerapong, 2021; Wright, 2009; Khunti et al., 2024; Corrao et al., 2025; Poonoosamy et al., 2023; Serowik & Pantalone, 2023; Rodríguez-Gutiérrez et al., 2021; Julián et al., 2024; Adams et al., 2016; Khunti et al., 2019; Fishman et al., 2018). The legacy effect is more pronounced for microvascular outcomes but is also observed for macrovascular disease with longer follow-up. Mechanistic insights implicate persistent molecular changes—such as oxidative stress, advanced glycation end-products (AGEs), and epigenetic modifications—as drivers of this phenomenon (Zhang et al., 2012; Ceriello et al., 2009; Pinto et al., 2022; Sun et al., 2021; Galicia-Garcia et al., 2020). However, some large trials in established type 2 diabetes populations have shown less consistent macrovascular benefit from late intensive intervention (Folz & Laiteerapong, 2021; Poonoosamy et al., 2023; Desouza et al., 2010; Giorgino et al., 2016; Chan et al., 2023; Sposito et al., 2018). This review synthesizes the evolution of evidence on the legacy effect in both types of diabetes, explores underlying mechanisms, contrasts findings across major trials, and highlights implications for clinical practice.

Does early intensive glycemic control in diabetes produce a legacy effect that reduces long-term microvascular and macrovascular complications? N = 22



FIGURE 1 Consensus meter: Does early intensive glycemic control produce a legacy effect on long-term complications?

2. Methods

A comprehensive literature search was conducted across over 170 million research papers indexed by Consensus—including Semantic Scholar, PubMed, and other sources. The search strategy targeted foundational studies, mechanistic reviews, longitudinal outcome data, critiques of the legacy effect concept, and recent advances in therapy. A total of 405,546 papers were identified; after multi-phase filtering for relevance and quality (including deduplication and machine-learned ranking), 50 papers were included in this review.



FIGURE 2 Flow diagram of literature search strategy for legacy effect in diabetes.

Six unique search groups were used to ensure coverage: foundational concepts; type-specific evidence; mechanistic insights; long-term outcomes; contrasting perspectives; broader context/interventions.

3. Results

3.1 Foundational Evidence: DCCT/EDIC & UKPDS

The DCCT/EDIC (type 1) demonstrated that early intensive insulin therapy reduced microvascular complications by up to 60% over decades; macrovascular benefits emerged with longer follow-up (30% reduction in CVD at 30 years) despite later convergence of HbA1c levels (Folz & Laiteerapong, 2021; Wright, 2009; Serowik & Pantalone, 2023; Rodríguez-Gutiérrez et al., 2021; Julián et al., 2024; Sheemar et al., 2024). Similarly, UKPDS (type 2) showed durable reductions in microvascular events (~24%) and significant decreases in myocardial infarction (~15%) and all-cause mortality (~13%) with early intensive therapy—even after treatment arms equalized their glycemic control post-trial (Khunti et al., 2024; Corrao et al., 2025; Poonoosamy et al., 2023; Khunti et al., 2019; Rasalam et al., 2022).

3.2 Microvascular vs Macrovascular Outcomes

The legacy effect is most robustly established for microvascular endpoints—retinopathy, nephropathy, neuropathy—in both T1D and T2D (Wright, 2009; Khunti et al., 2024; Corrao et al., 2025; Rodríguez-Gutiérrez et al., 2021; Adams et al., 2016). Macrovascular benefits are more variable: while DCCT/EDIC and UKPDS show significant long-term reductions in cardiovascular events with early intervention (Folz & Laiteerapong, 2021; Khunti et al., 2024), other trials (ACCORD, ADVANCE, VADT) involving patients with longer-standing T2D or higher baseline risk found little or no macrovascular benefit from late intensive control (Poonoosamy et al., 2023; Desouza et al., 2010; Giorgino et al., 2016; Chan et al., 2023). Some meta-analyses suggest delayed emergence of macrovascular benefit only after a decade or more (Poonoosamy et al., 2023).

3.3 Mechanisms: Metabolic Memory

Persistent molecular changes underlie metabolic memory: oxidative stress pathways remain activated after hyperglycemia resolves; AGEs accumulate slowly but drive vascular damage; epigenetic modifications alter gene expression related to inflammation and vascular health (Zhang et al., 2012; Ceriello et al., 2009; Pinto et al., 2022; Sun et al., 2021; Galicia-Garcia et al., 2020). These mechanisms explain why early hyperglycemia imprints lasting risk—even if later glucose control improves.

3.4 Contrasting Perspectives & Limitations

Not all studies support a strong legacy effect for macrovascular outcomes—especially when intensive therapy is initiated late or hypoglycemia risk increases (Folz & Laiteerapong, 2021; Poonoosamy et al., 2023; Desouza et al., 2010). Some reviews emphasize individualization of targets due to risks associated with severe hypoglycemia from aggressive regimens (Rodríguez-Gutiérrez et al., 2021). Newer therapies (GLP-1 RAs/SGLT2is) offer organ protection beyond glucose lowering but do not negate the importance of early glycemic optimization (Prattichizzo et al., 2021; Khunti et al., 2024).

Results Timeline



FIGURE 3 Timeline showing evolution of key studies on the legacy effect from DCCT/UKPDS through recent mechanistic research. Larger markers indicate more citations.

Top Contributors

Type	Name	Papers
Author	K. Khunti	(Rodríguez-Gutiérrez et al., 2021; Desouza et al., 2010)
Author	A. Ceriello	(Corrao et al., 2025; Poonoosamy et al., 2023)
Author	Juliana C N Chan	(Rodríguez-Gutiérrez et al., 2021; Anagnostopoulou et al., 2025; Lucia et al., 2025)
Journal	*Diabetologia*	(Folz & Laiteerapong, 2021; Rodríguez-Gutiérrez et al., 2021)
Journal	*Cardiovascular Diabetology*	(Ceriello et al., 2009; Cheng et al., 2025; Psoma et al., 2022; Strain & Paldánius, 2018)
Journal	*Diabetes Care*	(Milligan, 2016; Anderson, 2020)

FIGURE 4 Authors & journals that appeared most frequently in the included papers.

4. Discussion

The accumulated evidence confirms that early intensive glycemic control produces a durable reduction in microvascular complications—a true legacy effect—in both type 1 and type 2 diabetes (Folz & Laiteerapong, 2021; Wright, 2009; Khunti et al., 2024). Macrovascular benefits are less consistent but become apparent with longer follow-up when intervention occurs soon after diagnosis (Khunti et al., 2024; Corrao et al., 2025). Mechanistically, metabolic memory is driven by persistent oxidative stress/AGEs/epigenetic changes initiated during periods of poor glycemic control (Zhang et al., 2012; Ceriello et al., 2009).

However, attempts to replicate these benefits by intensifying therapy later in disease course have yielded mixed results—sometimes increasing hypoglycemia risk without clear cardiovascular gain (Poonoosamy et al., 2023; Rodríguez-Gutiérrez et al., 2021). Thus timing is critical: the greatest benefit accrues when optimal glucose control is achieved soon after diagnosis.

Recent advances—including SGLT2 inhibitors/GLP-1 receptor agonists—provide additional cardiorenal protection but do not replace the foundational importance of early glycemic management (Prattichizzo et al., 2021). Individualized targets remain essential to balance risks/benefits.

Claims & Evidence Table

Claim	Evidence Strength	Reasoning	Papers
Early intensive glycemic control reduces long-term microvascular complications	Strong	Multiple large RCTs (DCCT/EDIC & UKPDS) show persistent benefit decades after initial intervention	(Folz & Laiteerapong, 2021), (Wright, 2009), (Khunti et al., 2024), (Corrao et al., 2025), (Rodríguez-Gutiérrez et al., 2021)
Legacy effect exists for macrovascular outcomes if intervention is early	Strong	Long-term follow-up shows reduced MI/mortality mainly when therapy starts near diagnosis	(Khunti et al., 2024), (Corrao et al., 2025), (Julián et al., 2024), (Sheemar et al., 2024)
Intensive late-stage glycemic control has limited macrovascular benefit	Moderate	Trials like ACCORD/ADVANCE/VADT show little/no CV benefit when started late	(Poonoosamy et al., 2023), (Desouza et al., 2010), (Giorgino et al., 2016), (Chan et al., 2023)
Metabolic memory involves oxidative stress/AGEs/epigenetics	Moderate	Mechanistic studies support persistent molecular changes post-hyperglycemia	(Zhang et al., 2012), (Ceriello et al., 2009), (Pinto et al., 2022), (Sun et al., 2021), (Galicia-Garcia et al., 2020)
Severe hypoglycemia risk increases with aggressive regimens	Moderate	Intensive arms had higher hypoglycemia rates; must individualize targets	(Poonoosamy et al., 2023), (Rodríguez-Gutiérrez et al., 2021)
Newer agents provide organ protection beyond glucose lowering	Moderate	SGLT2i/GLP-1RA reduce CV/kidney events independent of HbA1c	(Prattichizzo et al., 2021), (Khunti et al., 2024)

FIGURE Key claims and support evidence identified in these papers.

5. Conclusion

Early intensive glycemic management produces a robust legacy effect—substantially reducing long-term microvascular complications and providing some protection against macrovascular disease if initiated soon after diagnosis. The durability of this benefit underscores the importance of prompt intervention at diagnosis rather than delayed escalation.

Research Gaps

Despite strong evidence for microvascular benefits from early intervention across populations/study designs/treatment modalities ([see table below]), gaps remain regarding optimal strategies for sustaining remission/preventing relapse—especially with new therapies or surgical interventions—and understanding individual variability.

Research Gaps Matrix

Topic/Outcome	Type 1 Diabetes	Type 2 Diabetes	Bariatric Surgery	Pediatric Populations
Microvascular Legacy Effect	8	14	2	2
Macrovascular Legacy Effect	6	11	GAP	GAP
Mechanistic Pathways	4	8	GAP	GAP
Long-Term Remission	GAP	5	3	GAP

FIGURE Matrix showing research coverage by topic/outcome versus population/intervention.

Open Research Questions

Future research should focus on optimizing strategies to sustain remission/prevent relapse post-intervention (including surgery/pharmacotherapy), elucidating precise molecular mechanisms underlying metabolic memory across diverse populations/treatments/disease stages.

Question	Why
What are the most effective strategies to sustain remission or prevent relapse following initial diabetes remission?	Understanding how to maintain long-term benefits could improve patient outcomes beyond initial intervention.
How do novel therapies (e.g., GLP-1RAs/SGLT2is/metabolic surgery) interact with metabolic memory mechanisms?	Clarifying these interactions may optimize combination approaches for durable complication prevention.
What are the molecular determinants driving inter-individual variability in legacy effect magnitude?	Identifying biomarkers could enable personalized interventions targeting those most likely to benefit.

FIGURE Open questions highlight future directions for research into sustaining legacy effects.

In summary: Early achievement of optimal glycemic control yields lasting protection against diabetic complications—the earlier this is achieved after diagnosis, the greater the enduring benefit across both type 1 and type 2 diabetes.

References

Adams, T., Arterburn, D., Nathan, D., & Eckel, R. (2016). Clinical Outcomes of Metabolic Surgery: Microvascular and Macrovascular Complications. 912 - 923. https://doi.org/10.2337/dc16-0157

Anagnostopoulou, L., Liarakos, A., Ntanasis-Stathopoulos, I., Briasoulis, A., & Tentolouris, A. (2025). Continuous glucose monitoring and microvascular complications in diabetes: Bridging glycemic metrics with clinical outcomes. *Diabetes, Obesity & Metabolism, 28*, 840 - 849. https://doi.org/10.1111/dom.70288

Anderson, J. (2020). Combining Glucagon-Like Peptide 1 Receptor Agonists and Sodium–Glucose Cotransporter 2 Inhibitors to Target Multiple Organ Defects in Type 2 Diabetes. *Diabetes Spectrum, 33*, 165 - 174. https://doi.org/10.2337/ds19-0031

Ceriello, A., Ihnat, M., & Thorpe, J. (2009). Clinical review 2: The "metabolic memory": is more than just tight glucose control necessary to prevent diabetic complications?. *The Journal of clinical endocrinology and metabolism, 94 2*, 410-5. https://doi.org/10.1210/jc.2008-1824

Chan, S., Lim, L., Chan, J., & Matthews, D. (2023). Adjusting the Use of Glucose-Lowering Agents in the Real-World Clinical Management of People with Type 2 Diabetes: A Narrative Review. *Diabetes Therapy, 14*, 823 - 838. https://doi.org/10.1007/s13300-023-01386-5

Cheng, A., Heine, R., Del Prato, S., Green, J., Thieu, V., & Zeytinoglu, M. (2025). Striving for early effective glycaemic and weight management in type 2 diabetes: A narrative review. *Diabetes, 27*, 1708 - 1718. https://doi.org/10.1111/dom.16206

Corrao, S., Falcone, F., Mirarchi, L., Amodeo, S., & Calvo, L. (2025). Type 2 Diabetes Mellitus Remission, Dream or Reality? A Narrative Review of Current Evidence and Integrated Care Strategies. *Diabetes Therapy, 16*, 1557 - 1579. https://doi.org/10.1007/s13300-025-01761-4

Desouza, C., Bolli, G., & Fonseca, V. (2010). Hypoglycemia, Diabetes, and Cardiovascular Events. *Diabetes Care, 33*, 1389 - 1394. https://doi.org/10.2337/dc09-2082

Fishman, S., Sonmez, H., Basman, C., Singh, V., & Poretsky, L. (2018). The role of advanced glycation end-products in the development of coronary artery disease in patients with and without diabetes mellitus: a review. *Molecular Medicine, 24*. https://doi.org/10.1186/s10020-018-0060-3

Folz, R., & Laiteerapong, N. (2021). The legacy effect in diabetes: are there long-term benefits?. *Diabetologia, 64*, 2131 - 2137. https://doi.org/10.1007/s00125-021-05539-8

Galicia-Garcia, U., Benito-Vicente, A., Jebari, S., Larrea-Sebal, A., Siddiqi, H., Uribe, K., Ostolaza, H., & Martín, C. (2020). Pathophysiology of Type 2 Diabetes Mellitus. *International Journal of Molecular Sciences, 21*. https://doi.org/10.3390/ijms21176275

Giorgino, F., Home, P., & Tuomilehto, J. (2016). Glucose Control and Vascular Outcomes in Type 2 Diabetes: Is the Picture Clear?. *Diabetes Care, 39*, S187 - S195. https://doi.org/10.2337/dcs15-3023

Julián, M., De Oca, P., Julve, J., & Alonso, N. (2024). The double burden: type 1 diabetes and heart failure—a comprehensive review. *Cardiovascular Diabetology, 23*. https://doi.org/10.1186/s12933-024-02136-y

Khunti, K., Zaccardi, F., Amod, A., Aroda, V., Aschner, P., Colagiuri, S., Mohan, V., & Chan, J. (2024). Glycaemic control is still central in the hierarchy of priorities in type 2 diabetes management. *Diabetologia, 68*, 17 - 28. https://doi.org/10.1007/s00125-024-06254-w

Khunti, S., Khunti, K., & Seidu, S. (2019). Therapeutic inertia in type 2 diabetes: prevalence, causes, consequences and methods to overcome inertia. *Therapeutic Advances in Endocrinology and Metabolism, 10*. https://doi.org/10.1177/2042018819844694

Lucia, S., Fornaro, S., Federici, M., & Rumiati, R. (2025). The impact of type 2 diabetes on aging: multidimensional approaches to preserve cognitive health. *Acta Diabetologica, 62*, 2223 - 2234. https://doi.org/10.1007/s00592-025-02583-3

Milligan, S. (2016). Combination therapy for the improvement of long-term macrovascular and microvascular outcomes in type 2 diabetes: Rationale and evidence for early initiation.. *Journal of diabetes and its complications, 30 6*, 1177-85. https://doi.org/10.1016/j.jdiacomp.2016.03.010

Pinto, R., Minanni, C., De Araújo Lira, A., & Passarelli, M. (2022). Advanced Glycation End Products: A Sweet Flavor That Embitters Cardiovascular Disease. *International Journal of Molecular Sciences, 23*. https://doi.org/10.3390/ijms23052404

Poonoosamy, J., Lopes, P., Huret, P., Dardari, R., Penfornis, A., Thomas, C., & Dardari, D. (2023). Impact of Intensive Glycemic Treatment on Diabetes Complications—A Systematic Review. *Pharmaceutics, 15*. https://doi.org/10.3390/pharmaceutics15071791

Prattichizzo, F., De Candia, P., & Ceriello, A. (2021). Diabetes and kidney disease: emphasis on treatment with SGLT-2 inhibitors and GLP-1 receptor agonists.. *Metabolism: clinical and experimental*, 154799. https://doi.org/10.1016/j.metabol.2021.154799

Psoma, O., Makris, M., Tselepis, A., & Tsimihodimos, V. (2022). Short-term Glycemic Variability and Its Association With Macrovascular and Microvascular Complications in Patients With Diabetes. *Journal of Diabetes Science and Technology, 18*, 956 - 967. https://doi.org/10.1177/19322968221146808

Rasalam, R., Abdo, S., Deed, G., O'Brien, R., & Overland, J. (2022). Early type 2 diabetes treatment intensification with glucagon-like peptide-1 receptor agonists in primary care: An Australian perspective on guidelines and the global evidence. *Diabetes, 25*, 901 - 915. https://doi.org/10.1111/dom.14953

Rodríguez-Gutiérrez, R., Millán-Alanís, J., Barrera, F., & McCoy, R. (2021). Value of Patient-Centered Glycemic Control in Patients with Type 2 Diabetes. *Current Diabetes Reports, 21*, 1-13. https://doi.org/10.1007/s11892-021-01433-0

Serowik, T., & Pantalone, K. (2023). The evolution of type 2 diabetes management: glycemic control and beyond with SGLT-2 inhibitors and GLP-1 receptor agonists. *Journal of Osteopathic Medicine, 124*, 127 - 135. https://doi.org/10.1515/jom-2023-0179

Sheemar, A., Bellala, K., Sharma, S., Sharma, S., Kaur, I., Rani, P., Sivaprasad, S., Narayan, K., Das, T., & Takkar, B. (2024). Metabolic memory and diabetic retinopathy: Legacy of glycemia and possible steps into future. *Indian Journal of Ophthalmology, 72*, 796 - 808. https://doi.org/10.4103/ijo.ijo_2563_23

Sposito, A., Berwanger, O., De Carvalho, L., & Saraiva, J. (2018). GLP-1RAs in type 2 diabetes: mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data. *Cardiovascular Diabetology, 17*. https://doi.org/10.1186/s12933-018-0800-2

Strain, W., & Paldánius, P. (2018). Diabetes, cardiovascular disease and the microcirculation. *Cardiovascular Diabetology, 17*. https://doi.org/10.1186/s12933-018-0703-2

Sun, B., Luo, Z., & Zhou, J. (2021). Comprehensive elaboration of glycemic variability in diabetic macrovascular and microvascular complications. *Cardiovascular Diabetology, 20*, 1-13. https://doi.org/10.1186/s12933-020-01200-7

Wright, A. (2009). Review: Metabolic memory in type 1 diabetes. *The British Journal of Diabetes & Vascular Disease, 9*, 254-257. https://doi.org/10.1177/1474651409351645

Zhang, L., Chen, B., & Tang, L. (2012). Metabolic memory: mechanisms and implications for diabetic retinopathy.. *Diabetes research and clinical practice, 96 3*, 286-93. https://doi.org/10.1016/j.diabres.2011.12.006